Inhibiting an enzyme called phosphoglycerate dehydrogenase prevented additional lung tissue scarring in a mouse model of pulmonary fibrosis, a study reports. The discovery means scientists might be able to develop a PF therapy by targeting the enzyme, which is involved in metabolism, or transforming food into energy. The enzyme is…
Inhibiting Enzyme Prevents Additional Lung Scarring, Chicago Study Finds
I had an experience last week that reminded me of how I am still adjusting to my changing energy levels. A friend stopped by to visit and we had a nice time catching up. She was here for an hour and a half, and I was sitting…
The U.S. Food and Drug Administration has granted Fast Track designation to PBI-4050, ProMetic Life Sciences’ potential treatment for idiopathic pulmonary fibrosis, or IPF. Regulators recently approved ProMetic’s Investigational New Drug application for PBI-4050 and the company’s design for pivotal Phase 2/3 clinical trials of the therapy. A pivotal…
If you’re a member of the PF community, you’re well aware of how little the general public knows about the disease. It’s important that we all work together to raise awareness. Awareness results in more fundraising efforts, which means more dollars, which means more research, and eventually, hopefully, that means…
With the exception of being on antibiotics again for a bacterial infection that tried to start in my ears, nose, and throat, I am feeling pretty well these days. I am tired, but that is to be expected, and most of my harder days now are from the…
After reading other columns on this site, I’ve come to realize I’m not the only person with a lung disease dealing with sleep issues. After being diagnosed with idiopathic pulmonary fibrosis (IPF) in early 2016, I don’t recall sleep ever having been a problem until recently, in the last…
Ofev (nintedanib) is effective at slowing idiopathic pulmonary fibrosis (IPF) progression in patients over time regardless of their degree of lung function at the beginning of treatment, according to new results from an extension of a Phase 3 clinical trial. Ofev, by Boehringer Ingelheim, was approved by the U.S. Food and Drug…
Researchers have identified a variation of the AKAP13 gene that they say increases people’s susceptibility to developing idiopathic pulmonary fibrosis. An article about their discovery, published in The Lancet Respiratory Medicine, is titled “Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.” Previous…
With the documented success rate and benefits of naturopathic treatment for various chronic illnesses, it is hard for patients not to consider how natural remedies might help with their personal diagnosis. Natural remedies such as the use of essential oils or organic supplements, and those grounded in Chinese medicine such…
The American Lung Association‘s website includes its “Inspire” forum dedicated to pulmonary fibrosis patients and caregivers. The online platform has more than a million members who discuss various topics and share practical advice and emotional support with others. It also allows users to stay up to date on news about research, new…
